Exploring the efficacy of Shexiang Tongxin extract pills in severe heart failure
Main Article Content
Keywords
severe heart failure, Shexiang Tongxin pill, clinical efficacy, cardiac function, inflammatory factors
Abstract
The clinical efficacy of Shexiang Tongxin pills (STP) on cardiac function, inflammation, and prognosis was investigated in patients with severe heart failure. A total of 140 patients with severe heart failure, diagnosed and treated at the Shaoxing Central Hospital and its affiliates, were divided into control and experimental groups. Patients in the control group received conventional treatment, while those in the experimental group were given STP plus conventional treatment. The cardiac functions, levels of inflammatory factors, and outcomes of 6-minute walk distance (6MWD) were assessed and compared after 12 weeks of intervention. Besides, the rehospitalization and mortality proportions were also determined during a 1-year follow-up. In addition, oxygen-glucose deprivation and reperfusion (OGD/R) were conducted to mimic the injury of H9c2 cells in heart failure; cell survival, cytotoxicity, apoptosis, and inflammatory factors were also evaluated. Post-intervention, patients in the experiment group demonstrated greater improvement in cardiac functions, especially regarding left ventricular end-diastolic diameter and N-terminal pro-B-type natriuretic peptide, which were significantly decreased, while left ventricular ejection fraction was significantly increased (P < 0.05). Further, the levels of inflammatory factors, including tumor necrosis factor-α, hypersensitive C-reactive-protein, and interleukin 6, were significantly lower (P < 0.05), and a superior 6MWD outcome was observed in patients from the experimental group, compared to the control group (P < 0.05). After 1-year follow-up, both rehospitalization rate and mortality were significantly decreased in the experimental group, compared to the control group (rehospitalization, 38.57% vs. 55.71%, and mortality, 12.86% vs. 27.14%, respectively; P < 0.05). Furthermore, STP increased cell survival and reduced cell apoptosis, cytotoxicity, and inflammatory response in cardiomyocytes induced by OGD/R. Shexiang Tongxin pill demonstrated significant and promising clinical effects in treating severe heart failure by ameliorating cardiac functions, reducing inflammatory factor levels, and improving patients’ prognosis. In addition, STP ameliorated cellular damage and inflammation at cellular level. Thus, STP demonstrated important clinical values.
References
Chang, C., Ren, Y., Su, Q., 2022. Exploring the mechanism of Shexiang Tongxin dropping pill in the treatment of microvascular angina through network pharmacology and molecular docking. Annals Of Translational Medicine 10:983. 10.21037/atm-22-3976
Ding, Y., Zhu, H.Y., Zhang, L.Z., Gao, B.B., Zhou, L., et al. 2021. Shexiang Tongxin dropping pill () reduces coronary microembolization in rats via regulation of mitochondrial permeability transition pore opening and AKT-GSK3β phosphorylation. Chinese Journal of Integrated Medicine 27: 527–533. 10.1007/s11655-019-3176-6
Di Palo, K.E. and Barone, N.J., 2020. Hypertension and heart failure: prevention, targets, and treatment. Heart Failure Clinics 16: 99–106. 10.1016/j.hfc.2019.09.001
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association; Chinese Heart Failure Association of Chinese Medical Doctor Association; Editorial Board of Chinese Journal of Cardiology, 2018. Chinese guidelines for the diagnosis and treatment of heart failure 2018. Zhonghua Xin Xue Guan Bing Za Zhi 46(10): 760–789. Chinese. 10.3760/cma.j.issn.0253-3758.2018.10.004
Huang, C., Qiu, S., Fan, X., Jiao, G., Zhou, X., Sun, M., et al. 2021. Evaluation of the effect of Shengxian decoction on doxorubicin-induced chronic heart failure model rats and a multicomponent comparative pharmacokinetic study after oral administration in normal and model rats. Biomedicine and Pharmacotherapy 144: 112354. 10.1016/j.biopha.2021.112354
Liao, M., Xie, Q., Zhao, Y., Yang, C., Lin, C., Wang, G., et al. 2022. Main active components of Si-Miao-Yong-An decoction (SMYAD) attenuate autophagy and apoptosis via the PDE5A-AKT and TLR4-NOX4 pathways in isoproterenol (ISO)-induced heart failure models. Pharmacological Research 176: 106077. 10.1016/j.phrs.2022.106077
Lin, S., Chu, J., Zhang, L., Chen, D., Xiao, F., Chen, H., et al. 2017. Protective effects of Shexiang Tongxin dropping pill on pituitrin-induced acute myocardial ischemia in rats. Molecular Medicine Reports 16: 3125–3132. 10.3892/mmr.2017.6963
Lin, Y.J., Jiao, K.L., Liu, B., Fang, L. and Meng, S., 2022. Antiplatelet and myocardial protective effect of Shexiang Tongxin dropping pill in patients undergoing percutaneous coronary intervention: a randomized controlled trial. Journal of Integrative Medicine 20: 126–134. 10.1016/j.joim.2022.01.001
Lin, S., Lin, J.M., Zhang, L., Chen, D.X., Xiao, F., Chen, H.W., et al. 2019. Shexiang Tongxin dropping pill protects against Na(2)S(2)O(4)-induced hypoxia-reoxygenation injury in H9c2 Cells. Chinese Journal of Integrative Medicine 25: 439–445. 10.1007/s11655-018-2976-4
Liu, H., Zhao, J., Pan, S., Zhu, Y., Fu, G., Tang, W., et al. 2021. Shexiang tongxin dropping pill protects against sodium laurate-induced coronary microcirculatory dysfunction in rats. Journal of Traditional Chinese Medicine (Chung i tsa Chih Ying wen Pan) 41(1): 89–97. 10.19852/j.cnki.jtcm.2021.01.011
Meng, H., Du, Z., Lu, W., Wang, Q., Sun, X., Jiang, Y., et al. 2021. Baoyuan decoction (BYD) attenuates cardiac hypertrophy through ANKRD1-ERK/GATA4 pathway in heart failure after acute myocardial infarction. Phytomedicine 89: 153617. 10.1016/j.phymed.2021.153617
Murphy, S.P., Ibrahim, N.E. and Januzzi, J.L., 2020. Heart failure with reduced ejection fraction: a review. Journal of the American Medical Association (JAMA) 324: 488–504. 10.1001/jama.2020.10262
Pan, J., Wang, Z.-H., Wang, X.-M., Zuo, K.-N., Zhou, J.-M., Wang, W., et al. 2021. Pharmacoeconomic evaluation of Shexiang Tongxin dropping pills combined with conventional western medicine treatment for coronary heart disease by Markov model. (Zhongguo Zhong Yao Za Zhi Zhongguo Zhongyao Zazhi China) Journal of Chinese Materia Medica 46: 1832–1838. 10.19540/j.cnki.cjcmm.20210209.501
Billingsley, H.E., Hummel, S.L., Carbone, S., 2020. The role of diet and nutrition in heart failure: A state-of-the-art narrative review. Journal of Progress In Cardiovascular Diseases 63:538–551. 10.1016/j.pcad.2020.08.004
Lu, Y., Chu, X., Zhang, J., Zhao, Y., Jin, C., Zhu, J., et al. 2020. Effect of Shexiang Tongxin dropping pill on stable coronary artery disease patients with normal fractional flow reserve and coronary microvascular disease: A study protocol. Journal of Medicine (Baltimore) 99:e22126. 10.1097/MD.0000000000022126
Xiong, M., Jia, C., Cui, J., Wang, P., Du, X., Yang, Q., et al. 2015. Shexiang Tongxin dropping pill attenuates atherosclerotic lesions in ApoE deficient mouse model. Journal of Ethnopharmacology 159:84–92. 10.1016/j.jep.2014.11.013
Tan, Y.F., Fu, Y.H., Zhang, M.Z., 2023. Shexiang Tongxin Dropping Pill Allieviates Heart Failure via Extracellula Matrix-Receptor Interaction Pathways Based on RNA-Seq Transcriptomics and Experimental Studies. Chinese Journal of Integrative Medicine 29:600–607. 10.1007/s11655-023-3633-0
Park, Y.S., Wang, W., Li, Y.D. and Liu, K., 2022. Network meta-analysis of six Chinese patent medicines for replenishing Qi and activating blood in treatment of chronic heart failure. Journal of Chinese Materia Medica (Zhongguo Zhong Yao Za Zhi) 47: 4221–4237. 10.19540/j.cnki.cjcmm.20220510.502
Qiu, R., Zhong, C., Wan, S., Zhang, Y., Wei, X., Li, M., et al. 2022. Developing a core outcome set for assessing clinical safety outcomes of cardiovascular diseases in clinical trials of integrated traditional Chinese medicine and western medicine: study protocol. Trials 23: 1–9. 10.1186/s13063-022-06166-3
Reddy, R. and Lucke-Wold, B., 2022. Primer of vein of galen malformation management. Journal of Pediatric Heath Care Medicine 5: 30–34.
Tai, C.J., El-Shazly, M., Yang, Y.H., Tsai, Y.H., Csupor, D., Hohmann, J., et al., 2022. The effectiveness of Fuzi in combination with routine heart failure treatment on chronic heart failure patients. Journal of Ethnopharmacology 289: 115040. 10.1016/j.jep.2022.115040
Truby, L.K. and Rogers, J.G., 2020. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. JACC Heart Failure 8: 523–536. 10.1016/j.jchf.2020.01.014
Tufan, A., Avanoğlu Güler, A. and Matucci-Cerinic, M., 2020. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turkish Journal of Medical Science 50: 620–632. 10.3906/sag-2004-168
Upadhya, B. and Kitzman, D.W., 2020. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clinical Cardiology 43: 145–155.
Wang, L., Xiang, L., Piao, S., Gong, X., Zhou, W., Feng, W., et al. 2021. The efficacy and safety of Chinese medicine fufang zhenzhu Tiaozhi capsule (FTZ) in the treatment of diabetic coronary heart disease: study protocol for multicenter, randomized, double-blind, placebo-controlled clinical trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 14: 2651–2659. 10.2147/DMSO.S309419
Yao, Y., Zeng, Z., Zhao, Y., Li, T., Liu, Y. and Chen, R., 2020. Effect of Shexiang Tongxin dripping pills on coronary microcirculation disorder and cardiac dysfunction in a porcine model of myocardial ischemia-reperfusion injury. Nan Fang Yi Ke Da Xue Xue Bao 40: 899–906. Chinese. 10.12122/j.issn.1673-4254.2020.06.19
Zang, Y., Wan, J., Zhang, Z., Huang, S., Liu, X. and Zhang, W., 2020. An updated role of astragaloside IV in heart failure. Biomedicine and Pharmacotherapy 126: 110012. 10.1016/j.biopha.2020.110012
Zhang, S., Liu, H., Fang, Q., He, H., Lu, X., Wang, Y., et al. 2021. Shexiang Tongxin dropping pill protects against chronic heart failure in mice via inhibiting the ERK/MAPK and TGF-β signaling pathways. Frontiers in Pharmacology 12: 796354. 10.3389/fphar.2021.796354
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.